Letter to the Editor

Lukas RadbruchLukas Radbruch, MD, and Saskia Jünger are with the Department of Palliative Medicine, University Hospital, Bonn, Germany. Aukje Mantel-Teeuwisse, PhD, PharmD, is with the Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands. Aaron Gilson, PhD, and James Cleary, MD, are with the Pain & Policy Studies Group, University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA. Sheila Payne, PhD, is with the International End-of-life-care Observatory, Lancaster University, Lancaster, UK. Willem Scholten is with the Access to Controlled Medicines Programme, World Health Organization, Geneva, Switzerland.Correspondence[email protected]

Saskia JüngerLukas Radbruch, MD, and Saskia Jünger are with the Department of Palliative Medicine, University Hospital, Bonn, Germany. Aukje Mantel-Teeuwisse, PhD, PharmD, is with the Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands. Aaron Gilson, PhD, and James Cleary, MD, are with the Pain & Policy Studies Group, University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA. Sheila Payne, PhD, is with the International End-of-life-care Observatory, Lancaster University, Lancaster, UK. Willem Scholten is with the Access to Controlled Medicines Programme, World Health Organization, Geneva, Switzerland.

Aukje Mantel-TeeuwisseLukas Radbruch, MD, and Saskia Jünger are with the Department of Palliative Medicine, University Hospital, Bonn, Germany. Aukje Mantel-Teeuwisse, PhD, PharmD, is with the Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands. Aaron Gilson, PhD, and James Cleary, MD, are with the Pain & Policy Studies Group, University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA. Sheila Payne, PhD, is with the International End-of-life-care Observatory, Lancaster University, Lancaster, UK. Willem Scholten is with the Access to Controlled Medicines Programme, World Health Organization, Geneva, Switzerland.

Aaron GilsonLukas Radbruch, MD, and Saskia Jünger are with the Department of Palliative Medicine, University Hospital, Bonn, Germany. Aukje Mantel-Teeuwisse, PhD, PharmD, is with the Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands. Aaron Gilson, PhD, and James Cleary, MD, are with the Pain & Policy Studies Group, University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA. Sheila Payne, PhD, is with the International End-of-life-care Observatory, Lancaster University, Lancaster, UK. Willem Scholten is with the Access to Controlled Medicines Programme, World Health Organization, Geneva, Switzerland.

James ClearyLukas Radbruch, MD, and Saskia Jünger are with the Department of Palliative Medicine, University Hospital, Bonn, Germany. Aukje Mantel-Teeuwisse, PhD, PharmD, is with the Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands. Aaron Gilson, PhD, and James Cleary, MD, are with the Pain & Policy Studies Group, University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA. Sheila Payne, PhD, is with the International End-of-life-care Observatory, Lancaster University, Lancaster, UK. Willem Scholten is with the Access to Controlled Medicines Programme, World Health Organization, Geneva, Switzerland.

Sheila PayneLukas Radbruch, MD, and Saskia Jünger are with the Department of Palliative Medicine, University Hospital, Bonn, Germany. Aukje Mantel-Teeuwisse, PhD, PharmD, is with the Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands. Aaron Gilson, PhD, and James Cleary, MD, are with the Pain & Policy Studies Group, University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA. Sheila Payne, PhD, is with the International End-of-life-care Observatory, Lancaster University, Lancaster, UK. Willem Scholten is with the Access to Controlled Medicines Programme, World Health Organization, Geneva, Switzerland.

Willem ScholtenLukas Radbruch, MD, and Saskia Jünger are with the Department of Palliative Medicine, University Hospital, Bonn, Germany. Aukje Mantel-Teeuwisse, PhD, PharmD, is with the Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands. Aaron Gilson, PhD, and James Cleary, MD, are with the Pain & Policy Studies Group, University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA. Sheila Payne, PhD, is with the International End-of-life-care Observatory, Lancaster University, Lancaster, UK. Willem Scholten is with the Access to Controlled Medicines Programme, World Health Organization, Geneva, Switzerland.

show all

REFERENCES

Gilson AM, Maurer MA, Ryan KM, Skemp-Brown M, Husain A, Cleary JF. Ensuring patient access to essential medicines while minimizing harmful use: a revised World Health Organization tool to improve national drug control policy. J Pain Palliat Care Pharmacother. 2011;25:246–251.
Google Scholar
World Health Organization. Ensuring Balance in National Policies on Controlled Substances—Guidance for Availability and Accessibility of Controlled Medicines. Geneva: WHO Press; 2011. Available from http://whqlibdoc.who.int/publications/2011/9789241564175_eng.pdf
Google Scholar
Lamas D, Rosenbaum L. Painful inequities—palliative care in developing countries. N Engl J Med. 2012;366:199–201.
PubMed Web of Science ®Google Scholar
Jacobsen R, Liubarskiene Z, Moldrup C, Christrup L, Sjogren P, Samsanaviciene J. Barriers to cancer pain management: a review of empirical research. Medicina (Kaunas). 2009;45:427–433.
Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Letter to the Editor

REFERENCES

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Letter to the Editor

REFERENCES

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date